



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

October 24, 2023: 5:00 – 8:30 p.m.

- **Executive Session** **5:00 - 6:00**

- **Introductions and Approval of DUR Board Minutes** **6:00 - 6:05**
(Public Comment Prior to Board Action)

- **DVHA Pharmacy Administration Updates** **6:05 - 6:10**

- **DVHA Chief Medical Officer Updates** **6:10 - 6:15**

- **Proposed 2024 DURB Meeting Schedule** **6:15- 6:20**

- **Follow-up Items from Previous Meetings** **6:20 - 6:20**
 - None at this time.

- **RetroDUR/ProDUR** **6:20- 6:30**
 - Introduce: Concurrent Use of Multiple Acute Migraine Medications

- **Clinical Update: Drug Reviews** **6:30-6:30**
(Public comment prior to Board action)
 - **Biosimilar Drug Reviews (criteria will be discussed with Cytokine Modulator class)**
 - Amjevita (adalimumab-atto)
 - Cyltezo (adalimumab-adbm)
 - Hadlima (adalimumab-bwwd)
 - Hulio (adalimumab-fkjp)
 - Hyrimoz (adalimumab-adaz)
 - Idacio (adalimumab-aacf)
 - Yuflima (adalimumab-aaty)
 - Yusimry (adalimumab-aqvh)

 - **Full New Drug Reviews**
(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)
 - None at this time.

- **New Managed Therapeutic Drug Classes** **6:30 - 6:30**
(Public comment prior to Board action)
 - None at this time.

- **Therapeutic Drug Classes – Periodic Review** **6:30 – 6:30**
(Public comment prior to Board action)
 - None at this time

- **Review of Newly Developed/Revised Criteria** **6:30 – 8:30**

(Public comment prior to Board action)

(All changes will be effective January 1, 2024, unless otherwise noted)

- ADHD Agents Long-Acting Stimulants/Amphetamine Products
- ADHD Agents Non-stimulant
- Allergen Extract Immunotherapy
- Anticonvulsants
- Overdose Treatments (effective 11/17/23)
- Anti-Parkinson's Agents
- Antiretrovirals/Single Product Regimens
- Antiretrovirals/Protease Inhibitors
- Antiretrovirals/Nucleoside & Nucleotide Analog RTIs
- Cytokine Modulators (Includes the following PDL classes):
 - Ankylosing Spondylitis Injectables
 - Inflammatory Bowel Disease Biologics
 - Hidradenitis Suppurativa
 - Psoriasis
 - Rheumatoid, Juvenile, & Psoriatic Arthritis Biologics
- Endometriosis/Uterine Fibroids Agents
- Gout Agents
- Hemophilia B Treatments
- Inhaled Corticosteroids (effective 11/17/23)
- Intranasal Antihistamines
- Multiple Sclerosis Agents
- Muscular Dystrophy
- Ophthalmic Antibiotics and Combinations (effective 11/17/23)
- Ophthalmic Immunomodulators/Dry Eye
- Otic Anti-infectives and Combinations (effective 11/17/23)
- Potassium Removing Agents
- Respiratory/Pulmonary Fibrosis Agents
- Respiratory Syncytial Virus Vaccines and Treatments (effective 11/17/23)
- Sickle Cell Agents
- Urinary Antispasmodics

- **General Announcements** **8:30 – 8:30**
None at this time.

- **Adjourn** **8:30**